WebMD1d
FDA OKs Triple Combo for Advanced Large B-Cell Lymphoma
The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).
The EMBO Journal1d
Portimine A toxin causes skin inflammation through ZAKα-dependent NLRP1 inflammasome activation
In 2020-2021, a mysterious skin disease affected fishermen in Senegal. High levels of Portimine A toxin, produced by the ...
Frontiers22d
Evaluating biomarkers in canine cytotoxic interface dermatitis reactions to account for clinical and histopathological similarities and differences
Skin biopsies from the biorepositories ... HCS, Hepatocutaneous Syndrome; CPV, Cell poor vasculitis; CCLE, Chronic cutaneous lupus erythematosus; CLE, Cutaneous lupus erythematosus; CTCL, Cutaneous T ...
Targeted Oncology29d
Extended SGX301 Treatment Shows Positive Results in Early-Stage CTCL
The phase 3 FLASH (NCT02448381) study evaluating SGX301 (HyBryte) has shown promising results, with over 70% of patients with early-stage cutaneous T-cell lymphoma (CTCL ... is topically applied to ...
Everyday Health29d
Stage 4 Lymphoma
Kinase Inhibitors These drugs block certain enzymes that control cell growth, helping to keep lymphoma cells from growing. Targeted therapy drugs may have side effects. The types of side effects ...